ADC Ther­a­peu­tics has raised $550M-plus in its quest for their first BLA — and here’s why that’s im­por­tant

Last week
Venture

Ger­man can­cer biotech BioN­Tech rais­es a mam­moth $325M in lat­est round, bring­ing to­tal haul to $1.4B+

Last week
Venture

More de­lays? Now Roche’s CEO says he’s will­ing to wait well in­to next year to com­plete their $4.3B Spark buy­out

Last week
Deals

In­tra-Cel­lu­lar fin­gers a high place­bo re­sponse ex­plain­ing a PhI­II fail­ure as lead drug goes 1-and-1 in de­pres­sion

Last week
R&D

Sang­amo/Pfiz­er are catch­ing up to Bio­Marin and Spark with a gene ther­a­py for he­mo­phil­ia A — can they leapfrog ahead?

3 weeks ago
Cell/Gene Tx
R&D

J&J dumps $915M de­vel­op­ment deal with Han­mi as an­oth­er Big Phar­ma aban­dons dis­as­ter-prone Ko­re­an drug­mak­er

3 weeks ago
Deals

Do ex­ec de­par­tures por­tend clin­i­cal dis­as­ters? An­a­lyst counts the ex­am­ples

3 weeks ago
R&D

Go­ing for it: GSK’s Hal Bar­ron out­lines a big PhI­II pro­gram for rheuma­toid arthri­tis — go­ing head-to-head with gi­ant ri­vals

3 weeks ago
People
R&D

Unum shares ric­o­chet low­er as pre­mier drug slams in­to its sec­ond safe­ty cri­sis, FDA slaps an­oth­er hold on PhI

3 weeks ago
R&D

Ex-FDA com­mish Scott Got­tlieb says he's 'very proud' of Pfiz­er post as top Dem at­tacks in­flu­ence ped­dling

3 weeks ago
People

Bull­ish Amarin dou­bling sales force in fast run-up to the big FDA de­ci­sion on Vas­cepa

3 weeks ago
R&D
Regulatory

Bay­er, Ver­sant back a $250M cell ther­a­py start­up on a quest to cre­ate off-the-shelf im­muno-on­col­o­gy ther­a­pies

3 weeks ago
Cell/Gene Tx
Venture

Se­duc­ing Pfiz­er: How Ar­ray’s team pa­tient­ly worked up the lad­der to win an $11.4B bid from Al­bert Bourla

4 weeks ago
Deals

Scor­ing Pfiz­er v Sarep­ta: This round on Duchenne gene ther­a­py goes to the lit­tle biotech, but the phar­ma Go­liath has plen­ty of punch left

4 weeks ago
R&D

Scott Got­tlieb tempts the FDA's fiercest crit­ics with his leap on­to Pfiz­er's board of di­rec­tors

4 weeks ago
People
R&D

Turned back at the FDA, Im­muno­Gen is ax­ing 220 staffers, sell­ing pro­grams and hun­ker­ing down for a new PhI­II gam­ble

4 weeks ago
R&D

As­traZeneca chal­lenges Roche on front­line SCLC af­ter seiz­ing an in­ter­im win — and Mer­ck may not be far be­hind

4 weeks ago
R&D

Top an­a­lyst finds a sil­ver lin­ing in Ab­b­Vie’s $63B Al­ler­gan buy­out — but there’s a catch

4 weeks ago
Deals

Af­ter rais­ing $158M, this up­start's founders have star back­ers and plans to break new ground in gene ther­a­py

4 weeks ago
Cell/Gene Tx
Startups

Ab­b­Vie's $63B buy­out spot­lights the re­turn of ma­jor M&A deals — de­spite the back­lash

4 weeks ago
Deals

Ab­b­Vie seals $63B deal to buy a trou­bled Al­ler­gan — spelling out $1B in R&D cuts

4 weeks ago
Deals

In sur­prise switch, Bris­tol-My­ers is sell­ing off block­buster Ote­zla, promis­ing to com­plete Cel­gene ac­qui­si­tion — just lat­er

4 weeks ago
Deals

Why would the FDA ap­prove an­oth­er con­tro­ver­sial drug to spur a woman’s li­bido with these da­ta? And why no ex­pert pan­el re­view?

5 weeks ago
Bioregnum
Pharma

Which top 10 big phar­mas have the most to gain — or lose — over the next 5 years?

5 weeks ago
Pharma
First page Previous page 12345 Next page Last page